“…Indium In 111 octreotide scanning confirmed the presence of somatostatin receptors within the tumor. Lutetium Lu 177 dotatate was administered intravenously at a dose of 200 mCi per dose every 8 weeks for 4 cycles. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We want to share a case report about a patient with a NET re-treated with (177)Lu-DOTATATE and a literature review about salvage treatment with PRRT. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Following this trend, we continued our evaluation of aprepitant-based (177)Lu-radioconjugates in terms of future oncological applications. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Professor Jun Lu talks about the driving force for his career pathway and his academic journey from chemical physics to materials science and electrochemistry, as well as his experience of being an Editorial Board Member for Communications Chemistry.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Therefore, the aim of this study was to demonstrate the feasibility of clinical quantitative low-count SPECT imaging during [(177)Lu]Lu-PSMA-I&T/[(225)Ac]Ac-PSMA-I&T treatment. METHODS: Eight prostate cancer patients (1000 MBq/8 MBq [(177)Lu]Lu-PSMA-I&T/[(225)Ac]Ac-PSMA-I&T) received a single-bed quantitative (177)Lu/(225)Ac SPECT/CT acquisition (1 h) at 24 h post treatment (high-energy collimator, 16 projections p. head à 3.5 min, 128 × 128 pixel). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Aiming to expand the application of the SST(2)R-antagonist LM4 (DPhe-c[DCys-4Pal-DAph(Cbm)-Lys-Thr-Cys]-DTyr-NH(2)) beyond [(68)Ga]Ga-DATA(5m)-LM4 PET/CT (DATA(5m), (6-pentanoic acid)-6-(amino)methy-1,4-diazepinetriacetate), we now introduce AAZTA(5)-LM4 (AAZTA(5), 1,4-bis(carboxymethyl)-6-[bis(carboxymethyl)]amino-6-[pentanoic-acid]perhydro-1,4-diazepine), allowing for the convenient coordination of trivalent radiometals of clinical interest, such as In-111 (for SPECT/CT) or Lu-177 (for radionuclide therapy). After labeling, the preclinical profiles of [(111)In]In-AAZTA(5)-LM4 and [(177)Lu]Lu-AAZTA(5)-LM4 were compared in HEK293-SST(2)R cells and double HEK293-SST(2)R/wtHEK293 tumor-bearing mice using [(111)In]In-DOTA-LM3 and [(177)Lu]Lu-DOTA-LM3 as references. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…CONCLUSIONS: In first individual cases, iRIT with [(177)Lu]Lu-6A10-Fab appears to be feasible and safe, without therapy-related side effects. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…PURPOSE: The aim of this study was to investigate very early radiographic PSMA PET response after one cycle of [(177)Lu]Lu-PSMA I&T radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC) and to assess its role in predicting overall response and survival. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Overexpression of somatostatin type 2 receptors (SSTR2) in PHEO/PGLs promotes interest in applying therapies using somatostatin analogs linked to radionuclides and/or cytotoxic compounds, such as [(177)Lu]Lu-DOTA-(Tyr(3))octreotate (DOTATATE) and AN-238. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In the present study, we searched for novel opportunities to increase tumor-specific uptake of the radiolabeled minigastrin analogue [(177)Lu]Lu-DOTA-(DGlu)(6)-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH(2) ([(177)Lu]Lu-PP-F11N), that targets the cholecystokinin B receptor (CCKBR) in human cancers. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Then, dosimetry was carried out with the two tools in 21 patients with neuroendocrine tumours after the first and second injection of 7.2 ± 0.2 GBq of [(177)Lu]Lu-DOTA-TATE (40 dosimetry analyses with each software). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In this study, a syngeneic breast tumor mouse model was used to investigate the effect of [(177)Lu]Lu-DOTA-folate as an immune stimulus to enhance anti-CTLA-4 immunotherapy. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Nevertheless, approximately thirty percent of patients do not respond to [(177)Lu]Lu-PSMA RLT. Here, we only reviewed and reported the evaluated factors and their impact on survival or biochemical response to treatment to have an overview of the potentialprognostic parameters in [(177)Lu]Lu-PSMA RLT. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Prostate specific membrane antigen (PSMA) is discussed as a theranostic target for PSMA-directed radioligand therapy ([(177)Lu]Lu-PSMA RLT). Here, we report on the correlation of [(68)Ga]Ga-PSMA uptake with histological PSMA expression and on our preliminary experience with [(177)Lu]Lu-PSMA RLT in relapsing HGG. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We aimed to determine clinical baseline characteristics to predict OS in patients receiving [(177)Lu]Lu-PSMA I&T RLT in a long-term follow-up. MATERIALS AND METHODS: Ninety-two mCRPC patients treated with [(177)Lu]Lu-PSMA I&T with a follow-up of at least 18 months were retrospectively identified. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: [(177)Lu]Lu-PSMA is a radioligand therapy used in metastatic castration-resistant prostate cancer (mCRPC). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: In our study, dosimetric evaluations were performed in thirty patients with NENs who underwent RLT with [(177)Lu]Lu-DOTATATE. The reference method (M0) calculated the cumulative absorbed dose performing dosimetry after each of the four cycles. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: We retrospectively analyzed 103 patients with metastatic, castration-resistant PC who were treated with [(177)Lu]Lu-PSMA I&T. We calculated SUV(mean), SUV(max), PSMA-avid tumor volume (TV), and total lesion PSMA (defined as PSMA-TV*SUV(mean)) on pre-therapeutic [(18)F]PSMA-1007 PET. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso